scispace - formally typeset
H

Huimin Lu

Researcher at Chinese Academy of Sciences

Publications -  12
Citations -  271

Huimin Lu is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Colitis & Proinflammatory cytokine. The author has an hindex of 6, co-authored 12 publications receiving 104 citations.

Papers
More filters
Journal ArticleDOI

Protective role of berberine on ulcerative colitis through modulating enteric glial cells-intestinal epithelial cells-immune cells interactions.

TL;DR: The study indicated the EGCs–IECs–immune cell interactions might function as a crucial paradigm in mucosal inflammation and provided an infusive mechanism of berberine in regulating enteric neurogenic inflammation.
Journal ArticleDOI

Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.

TL;DR: This study was designed to explore whether PDE4 inhibition by apremilast exerts protective effects in dextran sulfate sodium‐induced murine UC.
Journal ArticleDOI

Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis

TL;DR: Berberine significantly attenuated the experimental symptoms and gut inflammation of chronic UC and illustrated that OSM and OSMR intervention might function as the potential target in chronic UC.
Journal ArticleDOI

Heme protects intestinal mucosal barrier in DSS-induced colitis through regulating macrophage polarization in both HO-1-dependent and HO-1-independent way

TL;DR: Results showed that the modification of colon tissue microenvironment with heme supplementation plays a protective role in DSS‐induced colitis mice through regulating the macrophage polarization in both HO‐1‐dependent and HO‐ 1‐independent way, indicating a new choice to therapeutically modulate the macophage function and prevent IBD.
Journal ArticleDOI

DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models.

TL;DR: Investigations showed that DZ2002 relieved systemic sclerosis by regulating fibrosis TGF-β/Smad signaling pathway and would be a potential drug for the treatment of systemic sclerosis.